Indian stocks: Visit www.stage2stocks.com →

Greenwich LifeSciences, Inc.

Stage 1 · Basing · week 2

As of Oct 22, 2026, Greenwich LifeSciences is in Stage 1, the basing phase, now in week 2 (since Oct 9, 2026). It closed at $15.48, 53.9% below its 52-week high and below its 200-day average, which is rising.

Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers in the United States. More about the company

$15.48
-5.61% today
$227M · Micro cap
Market Neutral — Building

Pro read

Pro

Our read

Basing, not in an uptrend yet

Setup score

—

Momentum

Steady

Edge

—

Is GLSI early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…
Stage Cycle Timeline2023-08-16 → 2026-10-22
S4 14w
S4 37w
S2 14w
S3 16w
2023-08-162026-10-22
S1S2S3S4Setup score (0–10, dashed line at 5)
S4 14w → S1 6w → S2 4w → S3 2w → S4 1w → S3 2w → S2 11w → S3 7w → S2 7w → S3 9w → S4 37w → S1 7w → S2 5w → S3 2w → S4 8w → S1 1w → S2 14w → S3 16w → S4 9w → S1 2w current
Total tracked: 165 weeks across 20 stage runs.

GLSI among Biotechnology73rd of 591 by relative strength

All 591 →
Stocks in Biotechnology ranked by relative strength, with stage and one-month change
#StockStageRS1M
1GTBPStage 2 · wk 799−22.3%
2IOVAStage 2 · wk 1899+38.8%
3SLSStage 3 · wk 499−1.5%
4MRNAStage 2 · wk 1799+11.3%
5TWSTStage 2 · wk 3999−14.5%
6KODStage 2 · wk 499+172.1%
7ERASStage 3 · wk 599+0.7%
8CLYMStage 3 · wk 399−15.8%
…73GLSIStage 1 · wk 291−11.6%
vs 52W High
-53.9%
$7.85 lo$33.57 hi
53.9% below 52W high
Stock is basing below old highs. A volume-backed breakout to new highs would be the Stage 2 signal to watch.
Stage Maturity
Week 2
1w13w26w
Week 2, early base
How long this stock has been basing. Longer bases can produce stronger breakouts, but the breakout itself is the signal.
vs 200 DMA
-29.0%
200 DMA: $21.80 · rising
Stock is testing its 200 DMA as part of the base. Reclaiming and holding above it is a key Stage 2 prerequisite.
Rel Volume
0.75x
vs 50-day avg
Volume in Stage 1 basing is typically quiet. A surge in volume on an upside breakout is the signal to watch.
Trend Health
↓
Short-term trend rolling over
Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.
1M
-11.6%
3M
+19.3%
6M
-34.6%
YTD
-20.5%
1Y
+69.0%
Scan Membership
Breakout Watch
Latest: 2024-07-09
5 appearances in last 60 days. First seen: 2021-07-13.
A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding. Staying power in the scan says more about the trend than any single appearance.
Recent Stage Timeline
2026-10-22S1
Wk 2 · Vol 0.75x
2026-10-21S1
Wk 2 · Vol 0.54x
2026-10-20S1
Wk 2 · Vol 0.78x
2026-10-19S1
Wk 2 · Vol 1.18x
2026-10-16S1
Wk 2 · Vol 0.84x
2026-10-15S1
Wk 1 · Vol 0.63x
2026-10-14S1
Wk 1 · Vol 1.07x
2026-10-13S1
Wk 1 · Vol 2.53x
2026-10-12S1
Wk 1 · Vol 1.32x
2026-10-09S14→1
Wk 1 · Vol 0.97x
2026-10-08S4
Wk 10 · Vol 1.05x
2026-10-07S4
Wk 9 · Vol 1.19x
Moving averages & range
50 DMA
$16.65
200 DMA
$21.80
52W High
$33.57
52W Low
$7.85
5D Low
$14.55
Resistance levels (recent highs)
20d High
$18.59
60d High
$19.48
120d High
$29.23
250d High
$33.57
Next resistance
+20.1%
to 20d High
ROE
-986.3%
Profit margin 0.0%
Dividend Yield
0.00%
P/B 73.0

Greenwich LifeSciences: quick answers

What stage is Greenwich LifeSciences in?

As of Oct 22, 2026, Greenwich LifeSciences (GLSI) is in Stage 1, the basing phase. It entered Stage 1 on Oct 9, 2026 and is in week 2. What the four stages mean

Is Greenwich LifeSciences in an uptrend?

Not yet. Greenwich LifeSciences is in Stage 1, a base that can come before an uptrend. It trades 29.0% below its 200-day average, which is rising.

How far is Greenwich LifeSciences from its 52-week high?

Greenwich LifeSciences closed at $15.48 on Oct 22, 2026, 53.9% below its 52-week high of $33.57. Its 52-week low is $7.85.

How has Greenwich LifeSciences performed over the past year?

As of Oct 22, 2026, Greenwich LifeSciences is up 69.0% over the past year and down 20.5% so far in 2026.

Which sector and industry is Greenwich LifeSciences in?

Greenwich LifeSciences is in the Biotechnology industry, part of the Health Care sector.

About this companyHealth Care· Biotechnology

Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers in the United States. Its lead product candidate is GP2, a HER2/neu transmembrane peptide, which is in Phase III clinical trial to prevent breast cancer recurrences in patients. The company also develops FLAMINGO-01, which is in Phase IIb and 3 Phase I clinical trial designed to evaluate the safety and efficacy of GLSI-100 in HER2 positive breast cancer patients. Greenwich LifeSciences, Inc. was formerly known as Norwell, Inc. and changed its name to Greenwich LifeSciences, Inc. in March 2018. The company was incorporated in 2006 and is headquartered in Stafford, Texas.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.